IsoPlexis Corp (ISO) News
Filter ISO News Items
ISO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ISO News From Around the Web
Below are the latest news stories about IsoPlexis Corp that investors may wish to consider to help them evaluate ISO as an investment opportunity.
Earnings Scheduled For March 2, 2022Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) i... |
IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 20222021 revenue increased 66% over prior year period 2021 revenue increased 66% over prior year period |
IsoPlexis'' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
IsoPlexis Corporation 2021 Q4 - Results - Earnings Call PresentationNo summary available. |
IsoPlexis GAAP EPS of -$8.99, revenue of $17.25M beats by $0.13MIsoPlexis press release (ISO): FY GAAP EPS of -$8.99.Revenue of $17.25M (+66.2% Y/Y) beats by $0.13M.2022 Guidance: IsoPlexis expects full year 2022 revenue to be in the range of… |
IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. |
IsoPlexis to Participate in Three Upcoming Investor ConferencesBRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences. 11th Annual SVB Leerink Global Healthcare Conference, VirtualFireside Chat on Wednesday, February 16th at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern TimeCowen 42nd Annual Health Care Conference, Virtual Fireside Chat on Wednesday, March 9th at 6:10 a.m. Pacific Time / 9:10 a.m. Eastern TimeBa |
IsoPlexis'' Immune Monitoring Helps Identify Early Factors of Long COVIDIsoPlexis Corporation (NASDAQ: ISO ) has announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium. In the study, the researchers used IsoPlexis'' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as … Full story available on Benzinga.com |
IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVIDIsoPlexis Corporation (NASDAQ: ISO) has announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium. In the study, the researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as Long COVID. Authors followed 309 patients from initial clinical diagnosis to early-stage recovery from acute disease, spanning up to 2-3 months post-diagnosis, |
IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell PublicationSingle-cell functional proteomics identifies biological factors and immune cell types that drive Long COVID in convalescent COVID-19 patientsBRANFORD, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell Company, today announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium, in which researchers used IsoPlexis’ single-cell functional proteomics platform to identify factors that may predict su |